Horizon Pharma, Inc. (NASDAQ:HZNP)

CAPS Rating: 1 out of 5

Recs

0
Player Avatar zzlangerhans (99.74) Submitted: 2/25/2013 4:44:57 AM : Outperform Start Price: $2.17 HZNP Score: +11.75

As predicted, Horizon has continued to struggle as the company hemorrhages cash while they attempt to ramp up the marketing of their superfluous products Duexis and Rayos. Duexis did show a spark of life with the most recent earnings call, rising sequentially to 6M from 2.6M the previous quarter. I'll take a chance that the dip to the low end of recent range will be followed by a temporary upswing rather than a precipitous exploration of new lows.

Featured Broker Partners


Advertisement